{"nctId":"NCT04384107","briefTitle":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)","startDateStruct":{"date":"2020-07-01","type":"ACTUAL"},"conditions":["Pneumococcal Infections"],"count":694,"armGroups":[{"label":"V114","type":"EXPERIMENTAL","interventionNames":["Biological: V114"]},{"label":"Pneumococcal 13-valent Conjugate Vaccine (PCV13)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: PCV13"]}],"interventions":[{"name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]},{"name":"PCV13","otherNames":["Prevnar 13™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Japanese male or female\n\nExclusion Criteria:\n\n* Has a history of invasive pneumococcal disease (IPD)\n* Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine (PCV), or any diphtheria toxoid containing vaccine\n* Has a known or suspected impairment of immunological function\n* Has a history of congenital or acquired immunodeficiency\n* Has or his/her mother has a documented human immunodeficiency virus (HIV) infection\n* Has or his/her mother has a documented hepatitis B surface antigen-positive test\n* Has known or history of functional or anatomic asplenia\n* Has a history of autoimmune disease\n* Has a known neurologic or cognitive behavioral disorder\n* Has received a dose of any pneumococcal vaccine prior to study entry\n* Has received a blood transfusion or blood products, including immunoglobulins","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"6 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Solicited Injection-Site Adverse Events","description":"An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Following any injection with either V114 or PCV13 the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs were erythema, induration, pain, and swelling.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"89.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null},{"groupId":"OG001","value":"81.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null},{"groupId":"OG001","value":"24.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"79.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Systemic Adverse Events","description":"An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Following any of the injections with either V114 or PCV13, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were decreased appetite, irritability, somnolence, and urticaria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"24.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.6","spread":null},{"groupId":"OG001","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Vaccine-Related Serious Adverse Events","description":"A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants with a vaccine-related SAE following dose 1 (with either V114 or PCV13) was reported. Vaccine-related SAEs were counted starting after vaccine dose 1 through completion of study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Meeting the Serotype Specific Immunoglobulin G Threshold Value of ≥0.35 μg/mL for Each Serotype in V114 After Dose 3","description":"The anti-pneumococcal polysaccharide (PnPs) serotype-specific immunoglobulin G (IgG) response rates (percentage of participants meeting serotype-specific IgG threshold value of ≥0.35 μg/mL of participants administered V114 versus participants administered PCV13) for the 15 serotypes contained in V114 were determined using an electrochemiluminescence assay.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Serotype-Specific IgG for the 13 Shared Serotypes in V114 and PCV13 After Dose 3","description":"The anti-PnPs serotype-specific IgG Geometric Mean Concentrations (GMCs) of participants administered V114 versus participants administered PCV13 for the 13 serotypes shared in V114 and PCV13 were determined using an electrochemiluminescence assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":null},{"groupId":"OG001","value":"3.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.63","spread":null},{"groupId":"OG001","value":"1.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":null},{"groupId":"OG001","value":"3.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":null},{"groupId":"OG001","value":"3.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.51","spread":null},{"groupId":"OG001","value":"4.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":null},{"groupId":"OG001","value":"4.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.38","spread":null},{"groupId":"OG001","value":"5.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.09","spread":null},{"groupId":"OG001","value":"3.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.99","spread":null},{"groupId":"OG001","value":"12.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":null},{"groupId":"OG001","value":"3.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.44","spread":null},{"groupId":"OG001","value":"5.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.24","spread":null},{"groupId":"OG001","value":"5.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":null},{"groupId":"OG001","value":"2.95","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Serotype-Specific IgG for the 2 Unique V114 Serotypes After Dose 3","description":"The anti-PnPs serotype-specific IgG GMCs of participants administered V114 versus participants administered PCV13 for the 2 unique V114 serotypes was determined using an electrochemiluminescence assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.59","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Meeting the Serotype Specific IgG Threshold Value of ≥0.35 μg/mL for Each Serotype in V114 After Dose 4","description":"The anti-PnPs serotype-specific IgG response rates (percentage of participants meeting serotype-specific IgG threshold value of ≥0.35 μg/mL of participants administered V114 versus participants administered PCV13) for the 15 serotypes contained in V114 were determined using an electrochemiluminescence assay.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]}]},{"type":"SECONDARY","title":"GMC of Serotype-Specific IgG for Each Serotype in V114 After Dose 4","description":"The anti-PnPs serotype-specific IgG GMCs of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114 was determined using an electrochemiluminescence assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.74","spread":null},{"groupId":"OG001","value":"5.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":null},{"groupId":"OG001","value":"1.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":null},{"groupId":"OG001","value":"3.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.43","spread":null},{"groupId":"OG001","value":"6.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.05","spread":null},{"groupId":"OG001","value":"9.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.03","spread":null},{"groupId":"OG001","value":"10.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.80","spread":null},{"groupId":"OG001","value":"7.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.27","spread":null},{"groupId":"OG001","value":"5.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.51","spread":null},{"groupId":"OG001","value":"11.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.21","spread":null},{"groupId":"OG001","value":"5.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.88","spread":null},{"groupId":"OG001","value":"8.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.53","spread":null},{"groupId":"OG001","value":"7.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":null},{"groupId":"OG001","value":"6.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.42","spread":null},{"groupId":"OG001","value":"0.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":null},{"groupId":"OG001","value":"0.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer of Serotype-Specific Opsonophagocytic Activity for Each Serotype in V114 After Dose 3","description":"The anti-PnPs serotype-specific opsonophagocytic activity (OPA) and geometric mean titers (GMTs) of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114 was determined using a multiplexed opsonophagocytic assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"211.51","spread":null},{"groupId":"OG001","value":"322.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"660.68","spread":null},{"groupId":"OG001","value":"471.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3984.87","spread":null},{"groupId":"OG001","value":"4118.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1241.69","spread":null},{"groupId":"OG001","value":"1358.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9124.96","spread":null},{"groupId":"OG001","value":"11956.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8416.19","spread":null},{"groupId":"OG001","value":"10421.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22324.41","spread":null},{"groupId":"OG001","value":"27396.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2725.29","spread":null},{"groupId":"OG001","value":"3338.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14175.13","spread":null},{"groupId":"OG001","value":"12288.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3698.24","spread":null},{"groupId":"OG001","value":"3705.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2709.90","spread":null},{"groupId":"OG001","value":"3961.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2371.39","spread":null},{"groupId":"OG001","value":"2541.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11861.63","spread":null},{"groupId":"OG001","value":"18957.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5575.08","spread":null},{"groupId":"OG001","value":"9.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23888.79","spread":null},{"groupId":"OG001","value":"121.79","spread":null}]}]}]},{"type":"SECONDARY","title":"GMT of Serotype-Specific OPA for Each Serotype in V114 After Dose 4","description":"The anti-PnPs serotype-specific opsonophagocytic activity (OPA) and geometric mean titers (GMTs) of participants administered V114 versus participants administered PCV13 for the 15 serotypes contained in V114 was determined using a multiplexed opsonophagocytic assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"453.42","spread":null},{"groupId":"OG001","value":"854.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1444.00","spread":null},{"groupId":"OG001","value":"893.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4531.52","spread":null},{"groupId":"OG001","value":"6264.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1853.08","spread":null},{"groupId":"OG001","value":"2151.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12553.06","spread":null},{"groupId":"OG001","value":"17476.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9218.64","spread":null},{"groupId":"OG001","value":"14041.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15451.96","spread":null},{"groupId":"OG001","value":"18039.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3259.24","spread":null},{"groupId":"OG001","value":"5050.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8486.72","spread":null},{"groupId":"OG001","value":"5719.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7027.62","spread":null},{"groupId":"OG001","value":"5903.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8441.43","spread":null},{"groupId":"OG001","value":"10834.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4716.70","spread":null},{"groupId":"OG001","value":"3829.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11319.82","spread":null},{"groupId":"OG001","value":"30686.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5561.71","spread":null},{"groupId":"OG001","value":"35.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19899.34","spread":null},{"groupId":"OG001","value":"1183.52","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":347},"commonTop":["Injection site erythema","Injection site induration","Injection site swelling","Pyrexia","Irritability"]}}}